文献速递前列腺癌

转移性去势敏感性前列腺癌疾病负担定义的全谱比较:基于疾病结局与基因组学

Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-01-11

该回顾性研究纳入294例生化复发或转移性去势敏感性前列腺癌(mCSPC)患者,中位随访58.3个月,按CHAARTED、STAMPEDE及两种数值定义(≤3和≤5)分为低瘤负荷和高瘤负荷。四种定义下高瘤负荷均与更差的总生存(OS)显著相关,且84.7%患者分类一致;不一致分类者临床行为和突变谱更具侵袭性。

要点

  • 四种转移瘤负荷定义下,高瘤负荷患者的中位OS和至去势抵抗时间均短于低瘤负荷。
  • 高瘤负荷与更差OS显著相关:CHAARTED HR 2.89,STAMPEDE HR 3.82,数值≤3 HR 4.67,数值≤5 HR 3.76,均p<0.01。
  • 84.7%患者四种定义分类一致;不一致者临床行为和突变谱更具侵袭性。

核心结论

  • 四种转移瘤负荷定义在临床终点和遗传学上均确认了mCSPC的疾病谱,各定义在患者分类、结局和基因组成上总体相似;作者认为数值定义的简便性可能更受青睐,尤其在与转移灶定向治疗整合时,纳入肿瘤遗传学可能进一步优化当前转移定义。

研究设计与样本

  • 回顾性综述,纳入294例生化复发或mCSPC且肿瘤接受体细胞靶向测序的患者,中位随访58.3个月。

主要发现

  • 四种定义下高瘤负荷患者的中位OS和至去势抵抗时间均短于低瘤负荷患者。
  • 84.7%患者四种定义下转移瘤负荷分类不变。
  • 高瘤负荷与更差OS显著相关:CHAARTED HR 2.89(p<0.01),STAMPEDE HR 3.82(p<0.01),数值≤3 HR 4.67(p<0.01),数值≤5 HR 3.76(p<0.01);四种定义间高瘤负荷(p=0.95)和低瘤负荷(p=0.79)的OS相似。
  • 分类不一致者倾向于更具侵袭性的临床行为和突变谱。
  • 低瘤负荷且TP53突变患者病程更具侵袭性,rPFS更接近高瘤负荷疾病。

临床怎么用

  • 作者认为,鉴于各定义在分类、结局和基因组成上总体相似,数值定义的简便性可能更受青睐,尤其在与转移灶定向治疗整合时。
  • 作者认为,纳入肿瘤遗传学可能进一步优化当前转移定义。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several definitions have attempted to stratify metastatic castrate-sensitive prostate cancer (mCSPC) into low and high-volume states. However, at this time, comparison of these definitions is limited. Here we aim to compare definitions of metastatic volume in mCSPC with respect to clinical outcomes and mutational profiles. METHODS: We performed a retrospective review of patients with biochemically recurrent or mCSPC whose tumors underwent somatic targeted sequencing. 294 patients were included with median follow-up of 58.3 months. Patients were classified into low and high-volume disease per CHAARTED, STAMPEDE, and two numeric (≤3 and ≤5) definitions. Endpoints including radiographic progression-free survival (rPFS), time to development of castration resistance (tdCRPC), and overall survival (OS) were evaluated with Kaplan-Meier survival curves and log-rank test. The incidence of driver mutations between definitions were compared. RESULTS: Median OS and tdCRPC were shorter for high-volume than low-volume disease for all four definitions. In the majority of patients (84.7%) metastatic volume classification did not change across all four definitions. High volume disease was significantly associated with worse OS for all four definitions (CHAARTED: HR 2.89; p < 0.01, STAMPEDE: HR 3.82; p < 0.01, numeric ≤3: HR 4.67; p < 0.01, numeric ≤5: HR 3.76; p < 0.01) however, were similar for high (p = 0.95) and low volume (p = 0.79) disease across all four definitions. Those with discordant classification tended to have more aggressive clinical behavior and mutational profiles. Patients with low-volume disease and TP53 mutation experienced a more aggressive course with rPFS more closely mirroring high-volume disease. CONCLUSIONS: The spectrum of mCSPC was confirmed across four different metastatic definitions for clinical endpoints and genetics. All definitions were generally similar in classification of patients, outcomes, and genetic makeup. Given these findings, the simplicity of numerical definitions might be preferred, especially when integrating metastasis directed therapy. Incorporation of tumor genetics may allow further refinement of current metastatic definitions.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Sutera P, Van Der Eecken K, Kishan AU, et al. Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics. Prostate Cancer Prostatic Dis. 2022. PMID: 35013522. doi:10.1038/s41391-021-00484-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。